Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.00p -4.94% 38.50p 19,739 08:30:47
Bid Price Offer Price High Price Low Price Open Price
37.00p 40.00p 40.50p 38.50p 40.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.6 -0.2 -4.3 - 5.65

Aortech (AOR) Latest News

More Aortech News
Aortech Takeover Rumours

Aortech (AOR) Share Charts

1 Year Aortech Chart

1 Year Aortech Chart

1 Month Aortech Chart

1 Month Aortech Chart

Intraday Aortech Chart

Intraday Aortech Chart

Aortech (AOR) Discussions and Chat

Aortech (AOR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:56:3637.332,228831.71O
07:36:4539.905,7392,289.86O
07:30:4037.001,772655.64O
07:21:2838.0010,0003,800.00O
2018-06-20 16:15:0044.00100,00044,000.00O
View all Aortech trades in real-time

Aortech (AOR) Top Chat Posts

DateSubject
21/6/2018
09:20
Aortech Daily Update: Aortech International is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AOR. The last closing price for Aortech was 40.50p.
Aortech International has a 4 week average price of 32.50p and a 12 week average price of 30.50p.
The 1 year high share price is 69.50p while the 1 year low share price is currently 10.50p.
There are currently 14,686,608 shares in issue and the average daily traded volume is 271,196 shares. The market capitalisation of Aortech International is £5,654,344.08.
19/6/2018
10:11
someuwin: * Highly valuable portfolio of IP covering a family of medical grade polymers & medical devices. * £60m spent on R&D. * Over 4 million implants performed and seven years of successful clinical use * Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510(k) clearances, CE Marks, Australian TGA and Japanese Ministry of Health approvals. * Miton recently took 9% * A new holder bought 13% last week * New management team. New products being co-developed with key industry players. * Valuation only £6m. With £3m cash * 45p share price. Options set at 300p. Recent broker note (conservative) target 400p
15/6/2018
23:49
bones: INTRODUCTION AorTech International plc holds patents, know-how and trade secrets relating to a family of bio-compatible materials. A large range of polymers has been developed within the Elast-Eon(TM) family with different mechanical properties, such as hardness and elasticity. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA and Japanese Ministry of Health approvals. BACKGROUND After several years of under-performance, containing more than its fair share of failed strategies and legal disputes with customers, partners and an ex-CEO (settled amicably in December 2017 for an undisclosed sum paid to AOR), Aortech is finally clear for take off! A new strategy for the company, incorporating the benefits of its long held, valuable IP assets, has finally been revealed (in May 2018); new investors have been rounded up to join the patient ones and top personnel have been recruited. Fresh money is in the bank ready to exploit the new frontiers in cardiovascular medical devices and cosmetic implants. SOME STATS Market capitalisation (June 18) = £6 MILLION Cash in bank (June 18) = £3 MILLION Invested in current proven technology to date = £60 MILLION (including £30 MILLION in heart valve R&D) STRATEGY Aortech is now seeking to maximise value from its IP portfolio by developing certain products while maintaining what the directors believe to be a low cost/risk business model. As part of this strategy, the company is entering into a development and manufacturing agreement with RUA Medical - click here hTTp://www.ruamedical.com - a medical textiles manufacturer, and a development contract with Vascular Flow Technologies - click here hTTp://vascular-flow.com - a medical device development company. If successfully developed and approved by the relevant regulatory authorities, the company proposes to employ a lean sales and marketing strategy for its products, a distribution model to provide access to hospital markets and OEM sales of devices to other medical device companies. Initial product pipeline is to be: 1. Cardiovascular and soft tissue patches 2. Large bore grafts 3. Synthetic heart valve Three new non-executive directors have been recruited, two of whom are from the highest echelons of the cardiovascular world! John Ely (NED - Heart Valve Expert) Geoffrey Berg (NED - Cardiovascular Expert) See this RNS and Offer document for all the details about these products and new directors: hTTps://uk.advfn.com/stock-market/london/aortech-AOR/share-news/AorTech-International-PLC-Conditional-Placing-and/77473499 hTTps://www.aortech.net/wp-content/uploads/2018/05/249297-Project-Amplify-Circular-WEB.pdf INTRO VIDEO ABOUT AORTECH'S HEART VALVE Aortech acquired the original IP from CSIRO in the early 2000's - click this link hTTps://csiropedia.csiro.au/elast-eon-biocompatible-polyurethane/. Now AOR is finally funded to complete stage one of the quest to commercialise the holy grail that is the synthetic heart valve. This video is the basic introduction to the technology (note the reference to Aortech in it). !YOUTUBEVIDEO:qfzXvuh2xxc: RNS UPDATE 19th JUNE 2018 Development Agreement signed with Vascular Flow Technologies Limited ("VFT") Excerpt: Bill Brown, Chairman of AorTech, said: "In partnering with the team at VFT, AorTech now has access to Europe's leading experts in the combined field of medical imaging, guided Finite Element Analysis and Computational Fluid Dynamics. Combining the design history with this ground breaking imaging analysis should much improve the quality of the product design, reliability and performance." Craig Dunlop, General Manager and Director of VFT, said: "The team at VFT has been very impressed with the quantity and quality of data that AorTech has been able to demonstrate to us. We are very excited to be a key partner in the development of the next generation of prosthetic heart valves which should represent not only a step change in performance, but dramatically reduce the cost to manufacture these life enhancing devices." BROKER NOTE 400p INITIAL TARGET PRICE Stockdale Securities' report can be accessed via Research Tree but you have to sign up, albeit there is a free 7 day trial (with your payment details): hTTps://www.research-tree.com/companies/uk/medical-equipment-services/aortech-international/research/stockdale-securities/new-projects-to-drive-shareholder-value/ae347ba2-3cc8-47d7-8789-96d2eb7972f5 Excerpt:
12/6/2018
14:51
harrogate: Isn't the fact though that this company will never be valued on profits based on its current strategy - it is going to be lossmaking now for the foreseeable future as the money raised gets spent on both the developments and the increased corporate costs The share price will react to any positive news on developments around the heart valve. Given it is years away from any commercial revenue it is all about technical progress and the licensing deal that will be struck if that progress is exciting. The nature of that deal and the name of the licensee(s) will be what drives the value. That might be very exciting indeed but it will not be a slam dunk and I would have thought further funds will need to be raised. I see no reason to think that there is going to be a sudden and imminent large increase in the share price now.
24/5/2018
09:55
4x4guru: I for one are now more cautious about this stock, plus its my largest holding, it has a great potential in share price but recent activity and financials makes me think the share price could drop a bit lower due to increase risk. I can't work out how much money they are burning and what rate...?
16/5/2018
11:26
the stigologist: #AOR AorTech hTtps://www.aortech.net/ share price : 44p shares o/s : 5.6m mkt cap : £2.4m balance sheet cash : $0.5m? (Dec 2017 RNS : $328k as of Nov 2017) annual cashflow : c.$0.2m? (H1 Interims : Net Cash from Op. $172k) high quality cashflow from IPR licensing/royalty business model optionality from potential licensing of breast implant/heart valve biocompatible materials potential for use of company as a RTO/shell vehicle ? "The tax losses within the accounts also makes AOR attractive to a prospective buyer, as with millions to play with this could well prove to tempting to a profit making organisation" "£23M will attract deal makers. @20% that's £4.6M Discount that by 50% TAX LOSS IS WORTH MORE THAN TODAYS MARKET CAP" chart looks like it's breaking out (note last breakout above 50 day MA in November 2017 preceded big December 2017 150%+ move) Limited shares in issue, very tightly held
22/3/2018
15:20
the stigologist: I've worked in listed companies. Listed Investment Management companies to boot. You'd think employees in those sort of firms with heavy equity-linked remuneration and incentivisation would be obsessed by the share price? They're not. They get on with their day to day jobs and let the share price take care of itself. To use BB 'discourse' as some sort of metric to judge the fundamentals of a business is very very small time and idiotic behaviour.
15/3/2018
10:13
harrogate: Its a while since I have been in to see how things are through the looking glass of the alternative reality world of this board. I see things are little different with Stig here building a story around various pieces of information - of course that is what investment is about and good luck to him but please don't follow the hype. Surely it is clear here that the core material licensing business that was passed to Biomerics while valuable is not going to suddenly take off and as it was said in an RNS some AOR royalties from this arrangement have been taken upfront to pay AOR share of the additional costs in getting the manufacturing processes sorted at Biomerics - we don't know what that might be but it could mean that any new licence revenue doesn't flow to AOR for a good while. The hope here is all about the heartvalve - that is where the home run could be but do we really believe that our management can develop this? They will need significant money and a fundraise must be on the cards here and then it becomes a matter of the dilution and the partners they work with that must be announced at the same time. I am a very long term holder and while it is great that we have settled the court case and are not going bust we are a very long way from creating value beyond the current share price.
12/2/2018
23:53
bones: Well, there have been discussions in past RNS's about raising the necessary finance (from potential partners rather than AOR) to progress the trialling of AOR's work on the polymer heart valve. I have always gained the impression that AOR have an eye on more than just licensing in this field.Given the recent clearing up of legal disputes over the ex-CEO and his involvement with the heart valves IP, it still leaves questions hanging so we do need to hear what they have in mind in these strategic plans.Does the new NOMAD, Stockdale Securities, have an input here into ways of financing such developments? Will Biomerics be involved?Whatever the case, it should be a catalyst for share price movement.
30/1/2018
10:46
the stigologist: These are another set of notes I wrote after previous RNSes. Just FYI FWIW for any newbies getting up to speed. So the basics on this are that they developed this Elast-eon technology about 17 years ago. Failed to become a device manufacturer themselves. Licensed the materials tech unsuccessfully initially and on bad terms to much bigger players. Got into loads of litigation to try to protect their Intellectual Property etc. Finally seem to have drawn a line under previous litigation and found a licensing partner Biomerics who is delivering. Reckon that having learnt from previous experiences they can licence their tech successfully for some other devices e.g. Breast implants and Heart Valves. Their current valuation is totally out of sync with what even Private Start-ups are valued at (e.g. Edwards buying Harpoon a couple of weeks ago for $100-250m) which don't have the track record of successful clinical use or FDA approvals. AOR AorTech Share Price : 50p Market Cap : £2.8m AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals. Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available. Valuation comparitors :- Major licensee is Biomerics. Private Company. Recently spent $38m on a HQ building alone. hTtp://biomerics.com/elast-eon-bringing-quality-value-medical-device-project/ Edwards Lifesciences bought Harpoon Medical for $100-250m (December 6th 2017) hxxp://www.edwards.com/ns20171206 "The HARPOON system is designed to facilitate echo-guided repair of mitral valve regurgitation, by stabilizing the prolapsed mitral valve leaflet to restore proper coaptation and valve function" Xeltis achieved largest private equity funding round for a medical device in Europe of $52m in 2017 (November 15th 2017) hTtp://www.xeltis.com/news/xeltis-closes-e45-million-series-c-financing/ AorTech comments :- General licenses :- "Significant funding has been achieved by AorTech licencees in developing and commercialising their products with AorTech's Elast-Eon™ seen as critical to their success. In one instance, funds in excess of $100 million have been raised to achieve successful commercialisation." On their Heart Valve Project :- "We have previously announced a potential transaction with a new business established to commercialise the AorTech heart valve technology. Fund raising for the new project is continuing but is not yet finalised and any license will be dependent upon the new business being fully funded. The package of data and information that AorTech is able to deliver to the project is substantial. This ranges from specific manufacturing know how and trade secrets for the precise polymer best suited to a heart valve, detailed design files for a polymer valve with a stress/strain profile substantially less than the material mechanical properties, together with a fully documented manufacturing process that allows a clinical quality valve to be made on a repeatable basis. All of these processes have been developed over a number of years of trial and error and experimentation at considerable investment by AorTech."
15/12/2017
10:59
stephen2010: As I posted yesterday evening. Check out ALBA. Huge multibag potential. ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
Aortech share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180621 08:16:28